Allen Lee Cohn

Rocky Mountain Cancer Centers — United States

Medicine · Health Sciences

48h-index15.0kcitations230works5.32yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Colorectal Cancer Treatments and Studies(95), Cancer Treatment and Pharmacology(58), Lung Cancer Treatments and Mutations(50), Gastric Cancer Management and Outcomes(37), Hepatocellular Carcinoma Treatment and Prognosis(30)

Publications228 total

Use of yttrium-90 radioembolization to control liver metastases in pancreatic acinar cell carcinoma and pancreatoblastoma: Two case reports
World Journal of Gastroenterology·2026Open Access
Phase II study of tinengotinib in advanced cholangiocarcinoma: Analysis of molecular response and resistance mechanisms.
Journal of Clinical Oncology·2026
Tinengotinib for adults with advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 trial
˜The œLancet. Gastroenterology & hepatology·2025· 1 cited
1034MO Long-term follow-up of peptide receptor radionuclide therapy (PRRT)-naïve patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) treated with targeted alpha therapy 212Pb-DOTAMTATE in the phase II ALPHAMEDIX 02 trial
Annals of Oncology·2025
967P Phase I/II study of the next-generation Nectin-4-targeting antibody–drug conjugate CRB-701 (SYS6002) in patients with urothelial and non-urothelial solid tumours
Annals of Oncology·2025
1032O Efficacy and safety of targeted alpha therapy 212Pb-DOTAMTATE in patients with unresectable or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) previously treated with peptide receptor radionuclide therapy (PRRT): Results of a phase II study
Annals of Oncology·2025
Prognostic significance of blood-based multi-cancer detection in circulating tumor DNA (ctDNA): 5-year outcomes analysis.
Journal of Clinical Oncology·2025
POD1UM-303/INTERAACT2 subgroup analyses and impact of delayed retifanlimab treatment on outcomes in patients with squamous cell carcinoma of the anal canal (SCAC).
Journal of Clinical Oncology·2025
Activity of nab-sirolimus alone or in combination with cabozantinib, octreotide, or talazoparib in nonclinical neuroendocrine tumor models
Endocrine Abstracts·2025
Targeted alpha therapy with 212Pb-DOTAMTATE in subjects with advanced somatostatin receptor-expressing gastroenteropancreatic neuroendocrine tumors
Endocrine Abstracts·2025
Phase 2 study of nab-sirolimus in patients with well-differentiated and advanced/metastatic neuroendocrine tumors of the gastrointestinal tract, lung, or pancreas
Endocrine Abstracts·2025
Tinengotinib in patients with advanced, metastatic cholangiocarcinoma: Overall survival results and biomarker correlative analysis from a phase 2 clinical trial.
Journal of Clinical Oncology·2025· 1 cited
Tinengotinib for Adult Patients with Advanced or Metastatic Cholangiocarcinoma: A Multicenter, Open-Label Phase 2 Trial
SSRN Electronic Journal·2025Open Access
575P Phase Ib/II study of ompenaclid (RGX-202-01), a first-in-class oral inhibitor of the creatine transporter SLC6A8, in combination with FOLFIRI and bevacizumab (BEV) in RAS mutated (RASmt) second-line (2L) advanced/metastatic colorectal cancer (mCRC): Updated results
Annals of Oncology·2024
Safety, tolerability and efficacy of <sup>212</sup>Pb-DOTAMTATE as a targeted alpha therapy for subjects with unresectable or metastatic somatostatin receptor-expressing gastroenteropancreatic neuroendocrine tumors (SSTR+ GEP-NETs): A phase 2 study.
Journal of Clinical Oncology·2024· 15 cited
Lenvatinib plus Pembrolizumab Following Immune Checkpoint Inhibitor Treatment in Patients with Metastatic Clear Cell Renal Cell Carcinoma: Results from Study 111/KEYNOTE-146
European Urology·2024· 5 citedOpen Access
Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial
Journal for ImmunoTherapy of Cancer·2024· 57 citedOpen Access
Phase 2 study of <i>nab-</i>sirolimus in patients with well-differentiated and advanced/metastatic neuroendocrine tumors of the gastrointestinal tract, lung, or pancreas.
Journal of Clinical Oncology·2024
Efficacy and safety results of FGFR1-3 inhibitor, tinengotinib, as monotherapy in patients with advanced, metastatic cholangiocarcinoma: Results from phase II clinical trial.
Journal of Clinical Oncology·2024· 14 cited
Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146
Journal for ImmunoTherapy of Cancer·2024· 14 citedOpen Access
page 1 of 12Next →

Frequent Co-authors

Eric Van Cutsem(9), Josep Tabernero(8), Johanna C. Bendell(8), Takayuki Yoshino(6), Donald Richards(6), Mark Kozloff(6), Timothy Larson(5), Axel Grothey(5), David Cosgrove(4), Eric A. Klein(4), Charles Swanton(4), Michael V. Seiden(4), David R. Spigel(4), Radka Obermannová(4), G. Bodoky(4), Rocio García‐Carbonero(4), Tudor–Eliade Ciuleanu(4), David C. Portnoy(4), Jana Prausová(4), Federico Nasroulah(4)